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ABSTRACT Opisthorchiasis, caused by the foodborne trematode Opisthorchis viver-
rini, affects more than 8 million people in Southeast Asia. In the framework of a
phase 2b clinical trial conducted in Lao People’s Democratic Republic, pharmacoki-
netic samples were obtained from 125 adult and adolescent O. viverrini-infected pa-
tients treated with 400 mg tribendimidine following the design of a sparse sampling
scheme at 20 min and 2, 7.75, 8, and 30 h after treatment using dried blood spot
sampling. Pharmacokinetic data for the metabolites deacetylated amidantel (dADT)
and acetylated dADT (adADT) were pooled with data from two previous ascending-
dose trials and evaluated using nonlinear mixed-effects modeling. The observed
pharmacokinetic data were described using a ﬂexible transit absorption model for
the active metabolite dADT, followed by one-compartment disposition models for
both metabolites. Signiﬁcant covariates were age, body weight, formulation, and
breaking of the enteric coating on the tablets. There were signiﬁcant associations
between O. viverrini cure and both the dADT maximum concentration and the area
under the concentration-time curve (P  0.001), with younger age being associated
with a higher probability of cure. Modeling and simulation of exposures in patients
with different weight and age combinations showed that an oral single dose of
400 mg tribendimidine attained therapeutic success in over 90% of adult patients.
Our data conﬁrmed that tribendimidine could be a valuable novel alternative to the
standard treatment, praziquantel, for the treatment of O. viverrini infections.
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The foodborne trematode Opisthorchis viverrini is a human liver ﬂuke highly preva-lent in Southeast Asia, especially along the lower Mekong Basin. Infection occurs via
consumption of raw or undercooked cyprinid ﬁsh, mainly as part of local cultural eating
habits (1–3). The disease is generally asymptomatic in its acute phase but can develop
into a chronic stage that includes obstructive jaundice, gallstone formation, periductal
ﬁbrosis, and ascending cholangitis (4, 5). Moreover, O. viverrini is a major risk factor for
cholangiocarcinoma, a highly invasive bile duct cancer (3).
Treatment for O. viverrini infection relies exclusively on praziquantel, but the anthel-
mintic agent tribendimidine, initially marketed by Chinese authorities a decade ago for the
treatment of soil-transmitted helminthiasis (6), has the potential to be an alternative
effective drug to combat potential resistance against praziquantel. Tribendimidine has high
efﬁcacy against O. viverrini comparable to that of praziquantel and has an excellent safety
proﬁle (7, 8). After ingestion, tribendimidine is rapidly degraded into deacetylated amid-
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antel (dADT) and terephthalaldehyde (TPAL) without enzymatic involvement. dADT is
absorbed through the intestinal wall into the blood and is partially metabolized to form
acetylated dADT (adADT), while 35 to 55% is excreted unchanged in urine. TPAL is rapidly
and completely metabolized to terephthalic acid (TPAC), which is also excreted in urine (9,
10). The comparative activity of tribendimidine and its metabolites, assessed in vitro and in
vivo on the related Asian liver ﬂuke (Clonorchis sinensis), reveals that the trematocidal
activity is driven by dADT (11).
In the framework of a clinical development program, two phase 2a trials (68
patients) using single ascending doses of 25 to 600 mg evaluated the optimal dose of
tribendimidine for the treatment of O. viverrini infections (12) in Lao People’s Demo-
cratic Republic (Lao PDR). The trials, which included patients with mainly light infection
intensities, found cure and egg reduction rates above 61% and 97%, respectively, with
doses of 100 mg or more. The highest cure and egg reduction rates were observed for
a single oral dose of 400 mg tribendimidine (91.5 and 99.9%, respectively) or more (12).
A population pharmacokinetic (PK) analysis of these data showed that both the dADT
and adADT metabolites were well characterized by one-compartment disposition
models with linear elimination kinetics (13). In the present study, we pooled these data
with new PK data from 125 O. viverrini-infected adults treated with 400 mg tribendimi-
dine in the framework of a phase 2b trial (7). The combined data were used to develop
a pooled pharmacokinetic (PK)-pharmacodynamic (PD) model of tribendimidine me-
tabolites in the target adult population. In addition, the PK-PD model was used to
simulate exposure to the active dADT metabolite after 200- and 400-mg doses for
different age and weight combinations in order to guide dosing recommendations for
this novel treatment.
RESULTS
Participant characteristics, infections at baseline, treatment, and PK sampling.
In the phase 2b study, all 125 participants were treated as planned with a 400-mg single
dose, except for 2 patients who were wrongly dosed with 200 mg and therefore
included in modeling with the actual 200-mg dose received. The median age was
48 years, the median weight was 54 kg, and 54% of the participants were female (Table
1). The majority of the participants (90%, n 113) had a light O. viverrini infection
intensity at the baseline, with the mean egg count being 145.3 eggs per gram (EPG).
From each patient, 5 PK samples were obtained, with 93% of the samples being
collected within the planned windows (see Table S2 and Fig. S2 in the supplemental
TABLE 1 Summary of study design and demographicsa
Characteristic
Phase 2a study
Phase 2b study (3rd trial)1st trial 2nd trial 1st and 2nd trials
No. of patients 31 37 125
Dose 200 mg (n 13),
400 mg (n 9),
600 mg (n 9)
25 mg (n 9), 50 mg
(n 9), 100 mg
(n 9), 200 mg (n 10)
400 mg (n 123), 200 mg
(n 2, wrong dose)
Formulation 200-mg tablets 50-mg tablets 200-mg tablets
Median (range) age (yr) 42 (15–65) 48 (15–79)
Median (range) wt (kg) 52 (38–67) 54 (32–85)
% (no.) of female subjects 51 (35) 54 (68)
Sampling scheme Venous blood, 0, 1, 2, 3, 4,
4.5, 5, 6, 8, 10, and 24 h; DBS,
0, 1, 3, 4.5, 6, 10 h or
0, 2, 4, 5, 8, and 24 h
DBS, 0.33, 2, 7.75, 8,
and 30 h
Covariates Age, sex, ht, wt,
temp, blood pressure,
parasitology, pregnancy
Age, sex, ht, wt,
temp, blood pressure,
parasitology, pregnancy
Other clinical data Renal and hepatic functions
(azotemia, creatinine, ASAT-GOT,
ALAT-GOT)
aDBS, dried blood spots; ASAT, aspartate aminotransferase; GOT, glutamic oxalacetic transaminase; ALAT, alanine aminotransferase.
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material). As anticipated, at the ﬁrst sampling time point (20 min postdose), the
concentrations of both metabolites were below the lower limit of quantiﬁcation (LLOQ)
in most of the samples (85%), while overall, the concentrations were below the LLOQ
in 10% of the samples at later time points.
Pooled population PK modeling. One-compartment disposition models with a full
Stirling approximation implementation of the transit compartment absorption model
(5.27 theoretical compartments) where the absorption rate constant was assumed to
equal the transit rate constant best described the observed dADT and adADT
concentration-time data from the pooled studies (Fig. 1). Final population PK parameter
estimates are presented in Table 2. During initial model building, there was a signiﬁcant
FIG 1 Structure of the ﬁnal population PK model for tribendimidine. ktr, absorption transit rate constant; CLdADT,
dADT clearance; CLadADT, adADT clearance.
TABLE 2 Population PK parameter estimates from the ﬁnal model using pooled data from the two phase 2a trials and one phase 2b
triald
Parametera
Population estimate
(% RSE)b
95% CIc for
population estimate
% CV for BSV
(% RSE)b
95% CIc for
% CV for BSV
F (%) 100 (ﬁxed) 37.6 (8.20) 32.1 to 45.8
MTT (h) 3.18 (5.21) 3.05 to 3.73 54.1 (5.86) 49.9 to 66.2
No. of transit compartments 5.27 (13.4) 5.16 to 8.01 300 (6.01) 204 to 397
Metabolite dADT
CL/FdADT (liters/h) 15.8 (4.42) 15.1 to 17.9 19.7 (7.07) 16.6 to 22.5
V/FdADT (liters) 88.8 (4.93) 84.4 to 103 25.9 (7.41) 20.1 to 28.5
Whole blood-to-plasma matrix conversion factor (%) 14.5 (3.55) 19.4 to 7.41
DBS-to-plasma matrix conversion factor (%) 13.7 (3.96) 19.0 to 4.55
RUVplasma (% CV) 48.6 (6.30) 44.1 to 59.4
RUVwhole blood (% CV) 61.2 (6.36) 52.7 to 72.8
RUVDBS (% CV) 68.8 (7.93) 54.0 to 81.7
Metabolite adADT
CL/FadADT (liters/h) 65.8 (10.1) 59.6 to 87.0 116 (8.66) 105 to 172
V/FadADT (liters) 15.7 (9.89) 11.5 to 18.1 30.3 (46.8) 25.9 to 54.3
Whole blood-to-plasma matrix conversion factor (%) 5.00 (1.70) 2.16 to 9.51
DBS-to-plasma matrix conversion factor (%) 7.00 (4.15) 1.45 to 17.7
RUVplasma (CV%) 39.4 (7.58) 31.4 to 44.3
RUVwhole blood (% CV) 46.9 (6.34) 38.5 to 53.6
RUVDBS (% CV) 46.7 (10.8) 37.1 to 63.7
Covariate effects
Age on CL/FdADT (%) 1.19 (9.14) 1.35 to 0.88
Formulation on MTT (%) 42.9 (29.2) 16.0 to 61.4
Split 50-mg tablets on MTT (%) 79.4 (12.1) 100 to 60.2
aPopulation parameter estimates are presented for a typical patient at 45 years of age weighing 52 kg and receiving the 200-mg formulation as whole tablets and
with drug concentrations measured in plasma.
bComputed population mean values are from NONMEM. Between-subject variability (BSV) is calculated as expvariance1. Relative standard errors (RSEs) are
calculated as 100(standard deviation/mean value).
cBased on nonparametric bootstrap diagnostics of the ﬁnal PK model (n 1,000). The 95% conﬁdence intervals (CI) are displayed as the 2.5th to the 97.5th percentile
of bootstrap estimates.
dThe two phase 2a trials included 68 patients and have been described previously (16), and the phase 2b trial included 125 patients. dADT, deacetylated amidantel;
adADT, acetylated dADT; F, relative bioavailability; MTT, mean absorption transit time; CL/F, apparent elimination clearance; V/F, apparent volume of distribution; CV,
coefﬁcient of variation; DBS, dried blood spots; RUVplasma, residual unexplained variability for plasma; RUVwhole blood, residual unexplained variability for whole blood;
RUVDBS, residual unexplained variability for DBS; Age on CL/FdADT, linear covariate relationship between age and CL/FdADT centered on the median age of 45 years;
Formulation on MTT, the formulation effect on MTT (200 mg or 50 mg); Split 50-mg tablets on MTT, the effect of breaking the administered tablets (i.e., a 50-mg
tablet broken in half) on MTT.
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improvement in model ﬁt when a two-compartment disposition model rather than a
one-compartment disposition model was used (change in the objective function value
[ΔOFV] 102). However, this more complex two-compartment model did not provide
a signiﬁcant improvement in the ﬁt of the ﬁnal model compared to that of a one-
compartment disposition model. The two-compartment model was also unstable, and
further data would have been required to support this more complex disposition
model.
A systematic conversion factor between plasma and whole blood concentrations
improved the model ﬁt signiﬁcantly (ΔOFV 73), resulting in 13.7 to 14.5% lower and
5 to 7% higher drug concentrations in plasma than in blood for dADT and adADT,
respectively. The difference between drug concentrations measured in whole blood
and dried blood spots (DBS) was not statistically signiﬁcant.
Different drug formulations of 50 mg and 200 mg had a signiﬁcant impact on the
absorption transit rate constant (ΔOFV 56.7), resulting in a 42.9% slower mean
absorption transit time for the 200-mg formulation than for the 50-mg formulation. In
addition, breaking the tablet and thereby destroying the enteric coating (as was done
for some of the patients in the phase 2a trials) had a signiﬁcant impact on the
absorption transit rate constant (ΔOFV 79), resulting in a 79.4% faster mean absorp-
tion transit time for broken tablets than for whole 50-mg tablets. Age was found to be
a signiﬁcant linear covariate on dADT elimination clearance (ΔOFV 30.8), resulting in
a modest 1.19% decreased clearance per year increase in age.
Overall goodness-of-ﬁt diagnostics showed a reasonable model ﬁt without any
obvious model misspeciﬁcation (Fig. S5 and S6). However, the ﬁnal model resulted in
relatively high eta shrinkages associated with certain variability parameters (i.e., eta
shrinkages were 31% for apparent elimination clearance for dADT [CL/FdADT], 38% for
apparent volume of distribution for dADT [V/FdADT], 31% for relative bioavailability [F],
and 66% for apparent volume of distribution for adADT [V/FadADT]), and the individual
model ﬁts should be interpreted with caution. The prediction-corrected visual predic-
tive check (pcVPC) for dADT showed an adequate predictive performance with some
model misspeciﬁcation of the median percentile in the absorption phase and of the 5th
percentile in the disposition phase (Fig. 2, left). The pcVPC for the inactive metabolite,
FIG 2 Prediction-corrected visual predictive checks for dADT (left) and adADT (right) for the ﬁnal population PK model. Black circles represent observed data.
Dashed lines represent the 5th and 95th percentiles of observed data. Solid lines represent the 50th percentiles of observed data. Grey bands are the 95%
conﬁdence intervals for the corresponding simulated 5th, 50th, and 95th percentiles.
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adADT, presented overpredicted peak concentrations of the median percentile (Fig. 2,
right). The pcVPCs for the fraction of the data below the LLOQ for dADT (Fig. S3) and
adADT (Fig. S4) showed some model misspeciﬁcation during the absorption phase,
particularly in the DBS matrix. However, the misspeciﬁcation occurred before the peak
concentrations. Therefore, caution should be applied if the model is used for extrap-
olation during early absorption.
The PK parameter estimates are summarized in Table 3. As expected, dADT exposure
increased proportionally with dose, ranging from a maximum concentration (Cmax) of
61.4 ng/ml and an area under the concentration-time curve (AUC) of 509 ng·h/ml with
the 25-mg dose to a Cmax of 1,271 ng/ml and an AUC of 12,230 ng·h/ml for the 600-mg
dose. Overall adADT exposure was also proportional to the dose for all doses except the
200-mg dose, where the Cmax and AUC achieved with the 200-mg dose appeared to be
lower than those achieved with the 100-mg dose.
PK-PD analysis and exposure simulations. In the present phase 2b study, 1
patient was lost at follow-up, failing to present for the ﬁnal PD assessment at 21 days
following treatment. PK participants in the trial (n 124) had an average O. viverrini
egg reduction rate (ERR) of 99%, and 93% were cured of O. viverrini infection. Across
all three trials, 151/191 (79%) participants were cured, and visually, there was a clear
exposure-response relationship for O. viverrini infections, with higher Cmax or AUC
associated with higher ERRs (Fig. 3a and b). After adjustment for confounders, there
were strong associations between O. viverrini cure and both the dADT Cmax and the
dADT AUC (P 0.001; Table S3). Of note, younger age was associated with a higher
probability of cure, after adjustment for exposure.
In the univariable regression models of O. viverrini cure rates against exposure, the
90% probability of achieving a cure was estimated at a Cmax of 384 ng/ml and an AUC
of 4.520 ng·h/ml. Population-based simulations of the Cmax and AUC of dADT, stratiﬁed
by body weight (30 to 85 kg), from the ﬁnal PK model suggested that 400-mg ﬂat
dosing achieved the Cmax criterion of 384 ng/ml and the AUC criterion of 4,520 ng·h/ml
for all body weights (Fig. 4). A high variability in exposure was observed for all weight
groups.
DISCUSSION
Our pooled PK-PD study of tribendimidine in O. viverrini-infected adults and ado-
lescents in Lao PDR conﬁrmed that a single dose of 400 mg achieved adequate
exposure and high efﬁcacy (cure rates, 90%). This study adds to the evidence that
tribendimidine is a promising alternative treatment against opisthorchiasis, which,
when untreated, can result in potentially serious adverse health outcomes, including
cholangiocarcinoma (3).
TABLE 3 Secondary PK parameter estimatesa
Dose (mg) No. of subjects Cmax (ng/ml) Tmax (h) Half-life (h) AUC (ng·h/ml)
dADT
25 9 61.4 (55.5–71.7) 1.73 (1.22–2.03) 4.03 (3.67–5.03) 509 (418–525)
50 9 173 (160–228) 4.86 (3.87–8.15) 3.34 (2.96–3.42) 1,152 (1,042–1,489)
100 9 315 (279–366) 3.73 (2.56–5.55) 3.68 (3.46–4.07) 2,310 (1,966–2,433)
200 25 509 (411–722) 6.59 (4.57–9.40) 4.21 (3.65–4.92) 5,382 (4,280–6,477)
400 132 863 (594–1,102) 8.56 (6.84–11.1) 4.22 (3.63–5.15) 9,889 (7,871–12,758)
600 9 1,271 (626–1,254) 10.0 (3.95–10.9) 4.56 (3.95–5.16) 12,230 (10,736–17,794)
adADT
25 9 23.2 (4.30–32.0) 2.64 (2.01–2.84) 4.03 (3.67–5.03) 160 (40.3–224)
50 9 67.0 (13.6–68.7) 5.34 (4.40–8.22) 3.34 (2.96–3.42) 372 (114–518)
100 9 111 (95.3–123) 4.98 (3.16–5.74) 3.68 (3.46–4.07) 771 (639–987)
200 25 60.8 (32.0–227) 6.82 (4.80–9.47) 4.21 (3.65–4.92) 614 (365–2,165)
400 132 107 (57.8–264) 8.79 (7.02–11.8) 4.41 (3.72–5.21) 1,479 (740–3,660)
600 9 253 (235–361) 10.2 (4.28–11.1) 4.97 (3.95–5.17) 3,748 (2,678–5,050)
aCmax, maximum concentration; Tmax, time to reach maximum concentration; AUC, area under the concentration-time curve (0 to 72 h). All values are presented as the
median (range).
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The data obtained generated robust parameter estimates with reasonable precision,
therefore supporting the appropriateness of the current sampling design. The PK
properties of the main metabolites of tribendimidine, dADT and adADT, were best
described by a ﬂexible transit absorption model followed by a one-compartment
disposition model with ﬁrst-order elimination. Although data below the LLOQ were
handled by using Beal’s M3 method (14), some model misspeciﬁcation in the absorp-
tion phase remained for dADT. However, despite this potential misspeciﬁcation, the
peak concentrations were adequately predicted. Overpredicted peak concentrations
were seen with adADT, but given adADT’s minor role in the drug’s activity, this should
not be of any major concern in regard to therapeutic efﬁcacy or dosing assessments. A
two-compartment disposition model for dADT initially resulted in an improved model
ﬁt. However, when this initial structural model was rechallenged using the ﬁnal model,
FIG 3 Egg reduction rate (ERR) in O. viverrini among participants (n 190) from the 3 trials plotted by
the exposure parameters Cmax (a) and AUC (b).
FIG 4 Simulations (n 1,000) of the exposure, namely, AUC (left) and Cmax (right), stratiﬁed by body weight
after administration of a single oral dose of 400 mg tribendimidine. The dashed horizontal lines indicate the
AUC criterion (left) and the Cmax criterion (right) associated with the 90% probability of achieving a cure.
The AUC criterion is 4,520 ng·h/ml, and the Cmax criterion is 384 ng/ml. The box and whiskers represent 25th
to 75th and 10th to 90th percentiles, respectively.
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a two-compartment disposition model was not statistically superior to a one-
compartment disposition model. The two-compartment disposition model was also
unstable, and small perturbations of initial estimates resulted in different parameter
estimates, most likely reﬂecting the fact that not enough data were collected to support
a more complex structural disposition model.
Findings from the pooled analysis with respect to the model structure and covariate
effects corresponded to previously published PK modeling results for tribendimidine
(13). Clearance and volume parameters were scaled allometrically with body weight.
After adjustment for differences in body size, the clearance of dADT decreased approx-
imately 10% per 10-year increase in age, which might be due to declining renal
function with age (15). The mean absorption transit time was affected by the formu-
lation and tablet splitting. The pooled analysis combined data from a range of single-
dose treatment levels with two different enteric coating formulations. The 200-mg
tablets were used in the present phase 2b study, but drug administration in the phase
2a studies included a novel 50-mg formulation for some patients. The 200-mg formu-
lation resulted in slower absorption than those achieved with the 50-mg formulation.
This was previously explained by the reported in vitro physicochemical properties of the
200-mg formulation making it more likely to ﬂoat in the stomach, resulting in delayed
absorption (16). Breaking of the tablets resulted in faster absorption. This is expected,
since the destruction of the enteric coating is likely to cause an immediate release of
the drug (16). In contrast to the ﬁndings of Vanobberghen and colleagues (13), we
found that the addition of a conversion factor between plasma and blood concentra-
tions for dADT and adADT improved the model ﬁt signiﬁcantly.
We observed an exposure twice as high in O. viverrini-infected adolescents and
adults as in healthy Chinese volunteers (AUC, 9,889 ng·h/ml versus 4,769 ng·h/ml [17] or
4,450 ng·h/ml [9], respectively). In African children, an even higher total area under the
concentration-time curve from 0 h to inﬁnity (AUC0–inf) of 12,530 ng·h/ml was observed
(18). In all the studies, the same commercially available 200-mg tablets were used;
however, the studies differed with regard to the food intake or the fasting of the
participants. Whether the much higher exposure observed in O. viverrini-infected
participants than in healthy volunteers was achieved due to food intake or to disease
physiopathology is an important question which should be addressed in future re-
search. With the ﬂotation characteristic of currently marketed tribendimidine tablets,
the question of treating fasted or nonfasted patients could play an important role when
assessing the between-patient variability in dADT exposure.
In summary, the pooled population PK model presented here contributes to a better
understanding of the modalities of exposure to the main metabolites of tribendimidine,
dADT and adADT, in adult and adolescent patients. Simulations using the ﬁnal PK-PD
model showed that a single oral 400-mg dose of tribendimidine can uniformly achieve
a drug exposure associated with O. viverrini cure rates above 90%. The modeling
conducted here conﬁrmed that the formulation had a signiﬁcant impact on the
absorption of tribendimidine. This pooled study supports the development of
tribendimidine as a novel opisthorchicidal drug, but given the demonstrated variability
in drug absorption, there is a need to consider reﬁnements to the current formulation.
As noted above, tribendimidine presents signiﬁcant advantages over standard treat-
ment with praziquantel: a single and body weight-independent dose regimen that also
causes fewer side effects (7). In conclusion, tribendimidine is a promising alternative for
the treatment and control of opisthorchiasis.
MATERIALS AND METHODS
Study design and ethical considerations. The two phase 2a trials involving 68 patients treated with
50 to 600 mg tribendimidine were described previously (16). A noninferiority randomized controlled
phase 2b trial comparing tribendimidine (400 mg) and praziquantel (75 mg/kg) for the treatment of O.
viverrini infections was carried out in 607 adults and adolescents between February and April 2014 in the
district of Champasack in Lao PDR (7). Among the 295 patients from the tribendimidine treatment arm,
a subset of 125 adults, enrolled consecutively from those presenting in the morning and giving consent,
underwent PK sampling. Ethical clearance was given from the Ethics Committee of Northwestern and
Central Switzerland (EKNZ reference no. 375/11), the National Ethics Committee in Laos (009/NECHR), and
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the Liverpool School of Tropical Medicine (reference no. 12.02RS). The trial is registered at the ISRCTN
registry (ISRCTN96948551). Written, informed consent was obtained from all the patients before enroll-
ment into the study.
Patients, treatment, and study procedures. Prior to the beginning of the phase 2b trial, screening
for positive patients was performed with duplicate Kato-Katz thick smears (19) on two stool samples
collected within 5 consecutive days. Participants underwent a full medical checkup, including measure-
ment of weight, height, blood pressure, and axillary temperature and pregnancy assessment for female
participants. The rural setting of the trials did not allow the assessment of further biochemical and clinical
parameters (7). Eligible participants revealed no major systemic or chronic illness or psychiatric or
neurological disorders and were not pregnant. The participants were treated with a single oral dose of
400 mg tribendimidine using enteric-coated tablets of 200 mg (Shandong Xinghua Pharmaceutical
Corporation, Zibo, China) after a standard meal and were provided with water ad libitum. Adverse effects
were monitored over 24 h after drug administration. After 21 days posttreatment, the patients under-
went a second parasitological examination to assess treatment efﬁcacy using, again, 2 stool samples.
Values of the number of eggs per gram (EPG) were determined by adding the egg counts of the 4 slides
followed by multiplication by a factor of 6 (20). Cure of the participants was deﬁned as the percentage
of patients that were negative for O. viverrini infection (absence of eggs) at follow-up. Egg reduction rates
(ERR) were calculated using the following formula: ERR  [1  (geometric mean EPG at follow-up/
geometric mean EPG at baseline)]·100.
PK sampling and analysis. Dense PK sampling was performed in the phase 2a studies, collecting
venous blood samples at 0, 1, 2, 3, 4, 4.5, 5, 6, 8, 10, and 24 h postdose for both blood and plasma
concentration measurements. In addition, DBS samples were collected at 0, 1, 3, 4.5, 6, and 10 h for half
of the patients, while the other half was sampled at 0, 2, 4, 5, 8, and 24 h (16). A previous preliminary
analysis of these data was used to optimize a sparse PK sampling schedule in the phase 2b study (see
the ﬁles in the supplemental material). The sampling scheme in the phase 2b study consisted of the use
of ﬁve DBS samples taken from each patient at 0.32, 2.00, 7.75, 8.00, and 30.0 h after treatment within
the sampling windows of 0.27 to 0.85, 1.18 to 2.57, 6.28 to 7.85, 7.88 to 8.00, and 28.6 to 30.0 h,
respectively (Table 1, Table S1, and Fig. S1). Four blood drops were collected from each participant’s
ﬁngertip using lithium heparin-coated capillaries (volume 40 l; Alere 238 Cholestech LDX) and
deposited onto ﬁlter paper DBS cards (DMPK-C cards; Whatman, GE Healthcare Life Sciences, Cardiff, UK).
Samples were dried for 3 h before being transferred and stored in plastic bags with silica desiccants at
4°C. Tribendimidine, dADT, and adADT in the DBS samples were analyzed following a previously
published liquid chromatography-tandem mass spectrometry (LC-MS/MS) method (21). Brieﬂy, the
LC-MS/MS system was composed of a quaternary high-performance liquid chromatograph (Shimadzu,
Kyoto, Japan) coupled to an API 3000 tandem mass spectrometer (AB Sciex, MA, USA). The analytical
range for both metabolites was 1 to 2,000 ng/ml. The calibration curves were prepared with blood with
a hematocrit value of 35%, and quality control (QC) samples were assayed at 4 different concentrations
in 6 replicates each using blood with hematocrit values ranging from 25% to 50%. Acceptance criteria
for each analytical run were a mean accuracy of 85 to 115% (80 to 120% at the lower limit of
quantiﬁcation) for the calibration curve and for 4 out of 6 QC samples at each concentration.
Pooled population PK modeling. The population PK model for tribendimidine was developed using
pooled data from the 3 studies (two phase 2a trials, n 68 patients; one phase 2 b trial, n 125 patients)
(7, 12). All trial-speciﬁc details relevant to the PK analysis, including the tablet formulations and doses,
are summarized in Table 1. Population PK properties for dADT and adADT were characterized using
nonlinear mixed-effects modeling in the software NONMEM (version 7.3; ICON Development Solutions,
Ellicott City, MD, USA). The concentrations of dADT and adADT were transformed into their natural
logarithms and modeled sequentially using the population PK parameters and data (PPP&D) method
(22). To account for values below the LLOQ, occurring predominantly in the absorption phase (13% for
dADT and 21% for adADT in all matrices), Beal’s M3 method was used (14).
(i) Structural and stochastic model development. One-, two-, and three-compartment structural
models were explored to characterize the PK properties of dADT and adADT. The percentage of dADT
cleared renally was ﬁxed at 35%, based on a previously reported value (9), and the remaining 65% was
assumed to be metabolized to adADT. Zero-order and ﬁrst-order absorption with and without a lag time
was explored for the absorption process. Implementation of a transit compartment absorption model,
using the Stirling approximation (23), as well as adding transit compartments in a stepwise manner, was
also evaluated. Relative bioavailability was ﬁxed to unity, but between-subject variability (BSV) was
allowed. Population-based conversion factors were assessed for each of the compounds to compensate
for systematic differences between concentration measurements in different sampling matrices (i.e.,
venous plasma and whole blood as well as DBS) (24). A hypothetical intermediate transfer compartment
from dADT to adADT was evaluated to describe the formation of rate-limited elimination previously
reported for adADT (13). Additive and combined error models on log-transformed data were evaluated
to describe the residual unexplained variability. BSV was implemented using exponential models.
(ii) Covariate analysis. Potential covariates were assessed based on statistical signiﬁcance, biological
plausibility, and prior knowledge of factors inﬂuencing the PK properties of dADT and/or adADT (13).
Total body weight was implemented a priori as an allometric function, centered on the median body
weight, on clearance and volume parameters simultaneously using a ﬁxed exponent of 0.75 for clearance
and 1 for volume (25). Other covariates tested included age, sex, formulation, and the effect of breaking
the administered tablets (i.e., a 50-mg tablet broken in half in the phase 2a studies). Creatinine clearance
data were not available for all patients and could not be considered in this analysis. Covariates were
evaluated using a forward selection (P 0.05) and a backward elimination (P 0.001) approach. Linear,
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exponential, and power parameter-covariate relationships, centered on their median values for the
population, were tried.
(iii) Model discrimination and evaluation. Model discrimination was based on the likelihood ratio
test for nested models. A decrease in the objective function value (OFV) of 3.84 was considered
statistically signiﬁcant (P 0.05) when comparing hierarchical models with a 1-degree-of-freedom
difference. Models were evaluated using goodness-of-ﬁt and simulation-based diagnostics (prediction-
corrected visual predictive checks [pcVPCs]; n 1,000). In addition, the ﬁnal model was evaluated using
nonparametric bootstrap diagnostics (n 1,000), stratiﬁed by study, to obtain relative standard errors
(RSEs; in percent) and 95% conﬁdence intervals (CI) of the parameter estimates.
PK-PD analysis. The PK parameters evaluated for each metabolite included the maximum concen-
tration (Cmax), time to maximum concentration (Tmax), elimination half-life (t1/2), and total area under the
concentration-time curve from 0 h to inﬁnity (AUC0–inf), which were derived from the ﬁnal pooled
population PK model for all individuals in the three studies. To assess the relationship between treatment
outcome and drug exposure, cure of the O. viverrini infection as a function of the dADT Cmax or AUC was
modeled separately using multivariable logistic regressions with sex, age, and body mass index as
potential confounders.
Univariable logistic regressions of cure of O. viverrini infection against the dADT Cmax or AUC were
also performed to obtain a therapeutic criterion. The therapeutic criterion was deﬁned as a Cmax or AUC
value associated with a 90% probability of curing the infection (Cmax criterion or AUC criterion) (R
software, version 3.3.1).
Simulations of drug exposure stratiﬁed for weight. A single oral dose of 400 mg of tribendimidine
has been demonstrated to produce a cure rate of 92.6% in adults and adolescents aged 15 years (7).
Thus, the ﬁnal PK model was used to simulate a single oral dose of 400 mg in patients with a typical age
of 45 years and a body weight range of 30 to 85 kg at increments of 5 kg. A total of 1,000 virtual patients
were simulated per patient characteristic. The simulation was performed using the 200-mg formulation
since it is the most commonly used formulation. The simulation was performed using the 200-mg
formulation since it is the commonly used formulation. Simulated dADT Cmax and AUC stratiﬁed by
body weight were plotted to assess the probability of achieving therapeutic success at different
body weights. Successful treatment was deﬁned as Cmax or AUC values being above the Cmax
criterion or AUC criterion.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/AAC
.01391-18.
SUPPLEMENTAL FILE 1, PDF ﬁle, 1 MB.
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